Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Galmed Pharmaceuticals Ltd. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 10 | 12 | +2 |
| Shares | 5.60K | 44.8K | +39.2K (+699.4%) |
| Value | $38.3K | $142.8K | +$104.5K (+272.7%) |
New holders (3)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Schonfeld Strategic Advisors LLC | 25,400 | $81.0K | 0.00% |
| SBI Securities Co., Ltd. | 16 | $51 | 0.00% |
| Dogwood Wealth Management LLC | 1 | $3 | 0.00% |
Sold out (1)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| BNP Paribas Arbitrage, SA | 1 | $7 |